Senores Pharmaceuticals Announces Strong Q4 and FY26 Results, Highlights U.S. Expansion and Strategic Acquisitions

Senores Pharmaceuticals Announces Strong Q4 and FY26 Results, Highlights U.S. Expansion and Strategic Acquisitions​

Ahmedabad, Gujarat, May 14, 2026 — Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, announced its Audited Financial Results for the fourth quarter (Q4) and the full fiscal year (FY26) ended March 31, 2026. The company confirmed its strong operational and financial growth across key segments, alongside major strategic milestones, including the acquisition of Zoraya Pharmaceuticals and entering the U.S. federal market.

The company’s board meeting, held on Thursday, May 14, 2026, approved the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026. The statutory auditors, Pankaj R. Shah and Associates, issued an unmodified opinion on the financial results.

Financial Performance Highlights​

Senores Pharmaceuticals reported robust performance metrics for both the fourth quarter and the full fiscal year 2026.

Consolidated Financial Highlights (Q4 & FY26)​

The company posted significant year-over-year growth in key financial metrics:

Segmental Revenue Growth​

Revenue contributions were strong across major market segments, with Regulated Markets showing particularly high growth in Q4FY26.

Operational and Strategic Milestones​

Senores Pharmaceuticals reported several strategic achievements that bolster its growth strategy:

• U.S. Federal Market Entry: The company established a 70% joint venture, Amerisyn, in the U.S. This venture creates a direct pathway for supplying pharmaceuticals to federal, veterans, and defense sectors, opening access to a high entry barrier market.
• Acquisitions: The company advanced its presence through strategic acquisitions:

* It entered into an agreement to acquire a 51% membership interest in Zoraya Pharmaceuticals, LLC, a USA-based entity. This aims to strengthen vertical integration by allowing the commercialization of acquired ANDA portfolios under the dedicated Zoraya brand.
* Regarding Apnar Pharmaceuticals, Phase 1 completion was marked by the acquisition of a 75% stake. The balance 25% stake is expected to be completed by Q2FY27.
* Product Pipeline Strength: The Regulated Markets portfolio grew significantly, with the number of approved ANDAs increasing from 26 as of March 2025 to 51 as of March 2026. Of these, 30 approved ANDAs are yet to be commercialized, complemented by 27 additional ANDAs under development with over 65 strengths.

Financial Stability and Governance Updates​

On the financial front, the company noted a substantial improvement in cash flow generation. Cash Flow from Operations for FY26 reached Rs. 75 crores, showing marked improvement over the previous year, suggesting better conversion of EBITDA to operating cash flow.

In corporate governance matters, the Board of Directors approved the following:

• Resignation: Mr. Vinay Kumar Mishra resigned from the post of Company Secretary and Compliance Officer (Key Managerial Personnel), effective June 10, 2026.
• Internal Auditor Appointment: Sharp & Tannan Associates, Chartered Accountants (Firm Registration No. 109983W), was appointed as the Internal Auditor of the Company for FY 2026-27, based on the recommendations of the Audit Committee.

SENORES Stock Price Movement​

Senores Pharmaceuticals Limited shares today slipped by 1.41% to settle at ₹954.65 in post-market trading. The stock saw a volume of 1.64 million shares and remains notable for hitting its 52-week high of ₹991.